From Clinical Hopes to Investment Losses

During the pandemic, development of Genencell’s COVID-19 treatment candidate ‘ES16001’, promoted as a natural-product-based therapy, quickly drew attention, leading several listed companies to commit funds. However, even after approval of the Phase 2 and 3 clinical trial plan, a key turning point in development, the project failed to produce commercialization results. In the end, the corporate values and investment assets that had reflected those expectations were sharply impaired.

In the process, some companies faced not only paper losses but also management instability. The delisting decision issued against Sejong Medical and the case of Korea Pharma, which invested 3 billion won and later recognized losses, illustrate how weak the foundation was beneath the theme-driven capital formed during the infectious disease phase.

Suspicions Amplified by Political and Business Networks

The growing controversy was driven not only by a simple technological failure but also by the web of relationships surrounding the investment and regulatory approval process. Circumstances indicating that the KH side acquired Genencell shares for about 1.4982 billion won and went on to exchange executives heightened market doubts by suggesting the possibility of influence beyond an ordinary financial investment.

On top of that, it became known that a political figure had made contact around the same time as the Ministry of Food and Drug Safety’s review process, leading the market to question procedural fairness before technical merit. In biotech investment, trust in the approval process is as important as clinical results; once that trust is shaken, the damage can spread beyond the failure of an individual company and become a discount factor for the industry as a whole.

The Remaining Issue Is the Structure of Responsibility

What has emerged so far is that investment funds from multiple channels were not recovered, or the book value of investments was written down to zero. Combined with the fact that a related individual received a sentence of three years in prison, suspended for five years, on charges including submitting false materials, questions have grown over whether the failure stemmed simply from research-and-development risk or from problems in verification and control.

The significance of this case extends beyond the weakness of a single company. It has once again confirmed that when a fast-rising crisis narrative becomes intertwined with political connections, lax verification, and overheated capital, the losses are ultimately borne by retail shareholders at the bottom of the priority chain and by overall market trust.